Actively Recruiting
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Led by Massachusetts General Hospital · Updated on 2026-01-08
60
Participants Needed
4
Research Sites
640 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
I
Incyte Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). \- This research study involves the study drug Ruxolitinib.
CONDITIONS
Official Title
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with essential thrombocythemia or polycythemia vera by World Health Organization 2016 criteria
- For essential thrombocythemia: very low, low, or intermediate risk by IPSET criteria
- For polycythemia vera: low risk by NCCN guidelines
- MPN-SAF TSS (MPN-10) score above 10 and at least one symptom feature above 5 within 3 months before study
- Age 18 years or older
- ECOG performance status 2 or better (Karnofsky 60% or higher)
- Adequate organ and marrow function as defined by blood counts and liver/kidney tests
- Previously vaccinated for Herpes Zoster or willing to take prophylactic antiviral medication
- For chronic hepatitis B: undetectable viral load on therapy if needed
- For chronic HIV infection: negative for certain viral markers on suppressive therapy if needed
- Ability to understand and sign informed consent
You will not qualify if you...
- Essential thrombocythemia patients with high risk by IPSET-R criteria
- Polycythemia vera patients with high risk by NCCN guidelines
- More than 5% blasts in bone marrow or peripheral blood
- Receiving other investigational agents
- History of splenectomy (may be eligible after approval)
- Allergic reactions to ruxolitinib or its components
- Taking strong inhibitors of 3A4 enzyme
- Uncontrolled illnesses
- Inadequate liver or kidney function at screening
- Psychiatric or social conditions limiting study compliance
- Pregnant or breastfeeding women
- Unwillingness to use contraception if of childbearing potential or partner of childbearing potential
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
2
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Not Yet Recruiting
3
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
4
Massachusetts General North Shore Cancer Center
Danvers, Massachusetts, United States, 01923
Actively Recruiting
Research Team
G
Gabriela Hobbs, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here